The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma.

Authors

Jiadai Xu, Jing Li, Yuhong Ren, Luya Cheng, Zhixiang Cheng, Jingli Zhuang, Yang Ke, Shiyang Gu, Yian Zhang, Feifei Chen, Rupan Gao, Panpan Li, Yaqin Xiong, Peng Liu

Published in

Blood cancer journal. Volume 16. Issue 1. Jul 11, 2026. Epub Jul 11, 2026.

PMID:
42436125
Bibliographic data and abstract were imported from PubMed on 12 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.